Global Induced Pluripotent Stem Cells (iPSCs) Market Growth (Status and Outlook) 2025-2031

Global Induced Pluripotent Stem Cells (iPSCs) Market Growth (Status and Outlook) 2025-2031

The global Induced Pluripotent Stem Cells (iPSCs) market size is predicted to grow from US$ 125 million in 2025 to US$ 257 million in 2031; it is expected to grow at a CAGR of 12.8% from 2025 to 2031.

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The opportunities concerning a wide range of diseases including neurodegenerative, metabolic and cardiovascular diseases in a dish for cheaper and faster drug discovery. This may be particularly important in the context of monogenic rare hereditary diseases, where iPSCs can provide an alternative model system to compensate for the lack of a predictive in-vitro human model for drug discovery.

United States is the largest Induced Pluripotent Stem Cells (iPSCs) market with about 43% market share. Europe is follower, accounting for about 33% market share.

The key players are Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology, ReproCELL etc. Top 3 companies occupied about 73% market share.

LPI (LP Information)' newest research report, the “Induced Pluripotent Stem Cells (iPSCs) Industry Forecast” looks at past sales and reviews total world Induced Pluripotent Stem Cells (iPSCs) sales in 2024, providing a comprehensive analysis by region and market sector of projected Induced Pluripotent Stem Cells (iPSCs) sales for 2025 through 2031. With Induced Pluripotent Stem Cells (iPSCs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Induced Pluripotent Stem Cells (iPSCs) industry.

This Insight Report provides a comprehensive analysis of the global Induced Pluripotent Stem Cells (iPSCs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Induced Pluripotent Stem Cells (iPSCs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Induced Pluripotent Stem Cells (iPSCs) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Induced Pluripotent Stem Cells (iPSCs) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Induced Pluripotent Stem Cells (iPSCs).

This report presents a comprehensive overview, market shares, and growth opportunities of Induced Pluripotent Stem Cells (iPSCs) market by product type, application, key players and key regions and countries.

Segmentation by Type:
Human iPSCs
Mouse iPSCs

Segmentation by Application:
Academic Research
Drug Development and Discovery
Toxicity Screening
Regenerative Medicine
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Fujifilm Holding Corporation (CDI)
Ncardia
Sumitomo Dainippon Pharma
Astellas Pharma Inc
Fate Therapeutics, Inc
Pluricell Biotech
Cell Inspire Biotechnology
ReproCELL